Jon Stobo
YOU?
Author Swipe
View article: Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network
Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network Open
Background Neutrophilic airway inflammation is associated with disease severity and exacerbation frequency in bronchiectasis. Neutrophil protease inhibition significantly reduced exacerbation rates in phase II and III trials in bronchiecta…
View article: OS09.3.A FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
OS09.3.A FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Open
BACKGROUND The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has radio and chemosensitizing effects in preclinical models and penetrates GBM in patients at radiosensitizing concentrations. PARP inhibitors sensitize proliferating ce…
View article: The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study
The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study Open
The drivers of recurrence and resistance in ovarian high grade serous carcinoma (HGSC) remain unclear. We established BriTROC-1 to investigate the acquisition of resistance by collecting tumour biopsies from women with recurrent ovarian HG…
View article: A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease Open
View article: Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium Open
View article: P2.17-22 Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).
P2.17-22 Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy). Open
View article: PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status Open
View article: SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma Open
SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20 Gy/5#) or dose escalated treatment (36 Gy/6#) will be delivered using advan…
View article: ACTR-22. RESULTS OF PHASE I OF THE PARADIGM TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH SHORT COURSE RADIOTHERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
ACTR-22. RESULTS OF PHASE I OF THE PARADIGM TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH SHORT COURSE RADIOTHERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Open
BACKGROUND: Olaparib, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), has radiosensitising properties in pre-clinical GBM models. Because radiopotentiation is observed only in proliferating cells, we hypothesised that ola…
View article: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium Open
View article: Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study Open
Pain in mesothelioma varies among patients and may have neuropathic components. An adequate pain assessment is necessary to guide the clinician in the appropriate choice of analgesics.
View article: 16 The cardiac toxicity CMR study in patients with lung cancer treated with chemo-radiotherapy: The cart study- a semi quantitative analysis of the myocardial perfusion index
16 The cardiac toxicity CMR study in patients with lung cancer treated with chemo-radiotherapy: The cart study- a semi quantitative analysis of the myocardial perfusion index Open
Background There are limited data on the cardiac effects of radiotherapy and chemo-radiotherapy on the heart in patients with non-small cell lung cancer (NSCLC). CART is a pilot study designed to investigate change in myocardial function a…
View article: The cardiac toxicity CMR Study in patients with lung cancer treated with chemo-radiotherapy: The CART study- a semi quantitative analysis of the myocardial perfusion index
The cardiac toxicity CMR Study in patients with lung cancer treated with chemo-radiotherapy: The CART study- a semi quantitative analysis of the myocardial perfusion index Open
View article: F-18 FDG PET-CT Influences Target Delineation When Combined With Standard CT-Based Radiotherapy Planning in the Palliative Setting in Malignant Pleural Mesothelioma; an Exploratory Study
F-18 FDG PET-CT Influences Target Delineation When Combined With Standard CT-Based Radiotherapy Planning in the Palliative Setting in Malignant Pleural Mesothelioma; an Exploratory Study Open
Background: Positron emission tomography computerized tomography (PET-CT) is useful in radiotherapy planning for lung cancer. However, its role in malignant pleural mesothelioma (MPM) is unknown. Objectives: This exploratory study investig…
View article: PO-0667: Cardiac toxicity in lung cancer patients after chemo-radiotherapy (CART): a pilot study
PO-0667: Cardiac toxicity in lung cancer patients after chemo-radiotherapy (CART): a pilot study Open
View article: Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial Open